Genmab A (GMAB) Net Income towards Common Stockholders (2018 - 2026)

Genmab A has reported Net Income towards Common Stockholders for 6 years, with the latest figure at $74.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 69.67% year-over-year to $74.0 million; the trailing twelve-month figure through Mar 2026 stood at $979.0 million (up 21.77% YoY), and the FY2025 full-year result was $963.0 million, down 15.0% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $74.0 million, down from $482.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $482.0 million in Q3 2025, with the low at $74.0 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged $290.3 million across 3 years, with a median of $253.0 million in 2024.
• Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders jumped 90.51% — and 2026, when it sank 69.67%.
• Genmab A's Net Income towards Common Stockholders stood at $253.0 million in 2024, then soared by 90.51% to $482.0 million in 2025, then plunged by 84.65% to $74.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $74.0 million (Q1 2026), $482.0 million (Q3 2025), and $423.0 million (Q2 2025), per Business Quant data.